

MSD to develop new biotechnology facility in Dublin, with the expected creation of up to 350 new jobs

13th February 2018: Pharmaceutical company, MSD, is to develop new biotechnology facility in Swords, Co Dublin, with the expected creation of up to 350 new jobs. Known as **MSD Biotech, Dublin**, the facility will be constructed on an existing MSD-owned property, the site of its former facility in Swords.

It will play a pivotal role in the manufacture of MSD's biologics-based medicines, including in the area of immuno-oncology, and will expand MSD's current internal network of biologics drug substance manufacturing plants. Site preparation and facility design will commence immediately. Full manufacturing operations are expected to begin in 2021.

The company said that the decision to locate this new facility in Ireland was testament to the talent of MSD's Irish employees and the high standard of its existing operations and reinforces MSD's commitment to Ireland.

Last year the company announced plans to will create 330 new jobs and invest €280 million up to 2020 at two of its three other Irish manufacturing sites. The new jobs announced in Carlow and Cork were as a result of increased global demand for MSD's medicines and vaccines produced in Ireland, while the investment will see both sites expand production facilities and capacity to meet that demand.

MSD currently employs over 1,700 people across four sites in Ireland – in Carlow, Cork, Dublin and Tipperary. Its extensive Irish operations, encompassing manufacturing, commercial and marketing facilities, had a turnover of €4.7 billion in 2016.

MSD has a strong legacy in Ireland that stretches back over the last 50 years, and has seen the company invest over \$2.5 billion in expanding and developing its facilities here. The company provides healthcare solutions and innovative medicines in areas such as diabetes, heart disease, immuno-oncology, infectious diseases and vaccines.

MSD in Brinny, Co. Cork is an integrated site for the development, testing and manufacturing of biologics, specialising in the fermentation, purification and sterile filling of biotech products. Brinny produces some of the company's important treatments – medicines for lung cancer, melanoma, hepatitis C and rheumatoid arthritis.

MSD in Carlow is a state-of-the-art manufacturing facility, and the company's first stand-alone vaccine and biologics facility outside the US. Carlow also is an important link in the company's global network of sites producing MSD's new immuno-oncology treatment for the global market.

MSD's other existing Irish site is in Ballydine, Co. Tipperary. MSD Ballydine develops and supplies the active ingredients and final formulated product for a range of innovative medicines at its manufacturing and R&D facilities. The plant exports to over 30 countries around the world with primary markets being Europe, USA and Japan.

The company also has significant Human Health and Animal Health operations based in Leopardstown in Dublin.

MSD continues to significantly invest in R&D to invent new vaccines and medicines for areas of unmet need. In early February, 2018, the Company announced its plans to invest \$12 Billion globally over 5 years in capital projects, with \$8 Billion of that investment to be made in the U.S.

Details on open roles at MSD are available at www.msd.ie/careers

ENDS